AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01205503
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60mg/m2 given IV over 15 minutes after receiving mesna or saline. Can allow for premedications of Ondansetron 8 mg orally, dexamethasone 12 mg orally, Aprepitant 125 mg orally.
Trial: NCT01205503
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2 IV over 30 minutes. Start 6 hours after doxorubicin started.
Trial: NCT02765399
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04846335
Drug: Doxycycline Hcl
RxNorm normalized name: doxycycline HCl
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets of DOXY hydrocloride (Bassado)
Trial: NCT04846335
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets of placebo
Trial: NCT03358030
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT00716274
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, daily, for 16 weeks
Trial: NCT01932788
Drug: Placebo gummy vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to receive placebo, also in gummy form but manufactured without Vitamin D3, will consume 4 gummies/day beginning at 10-14 weeks of pregnancy. All subjects will take a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of pregnancy.
Trial: NCT00405288
Drug: Proctofoam-HC®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observational study of the exposure to Proctofoam-HC®
Trial: NCT01193452
Drug: S-1, Leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 :~The initial dosage of S-1 is determined by the body surface area:~Surface area: 1.25-1.5 m2 : 50mg twice per day;upper than 1.5 m2 : 60mg twice per day~Leucovorin:~25mg twice per day po.~The treatment is given for one week,and no chemotherapy is given for the following one week.
Trial: NCT01193452
Drug: leucovorin, 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: leucovorin: 400mg/m2 intravenous infusion d1;~5-fluorouracil: 400mg/m2 intravenous push,d1; 2400mg/m2 continuous intravenous infusion for 46 hours~repeat every 2 weeks
Trial: NCT02394158
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02323230
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low dose cyclophosphamide will be taken by mouth
Trial: NCT02109614
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator arm will be taking 1500mg of the placebo daily
Trial: NCT02723084
Drug: ABT-493/ABT-530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-formulated tablet
Trial: NCT02470702
Drug: Placebo (D5W)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04930679
Drug: Andiabet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each hard capsule includes: 200mg Gynostemma Pentaphyllum Leaf, 200mg Largerstroemia Speciosa Leaf, 133mg Anemarrhena Asphodeloides Whole
Trial: NCT01342926
Drug: GSK933776
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK933776
Trial: NCT01342926
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00002593
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV as described in Arm Description
Trial: NCT00002593
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV as described in Arm description.
Trial: NCT04422431
Drug: Bis-Choline Tetrathiomolybdate
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be initiated at 15 milligrams once daily, then the dose will be increased to 30 milligrams once daily at Week 6.
Trial: NCT00654173
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00654173
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00752414
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: same frequency as MP-376
Trial: NCT03695445
Drug: Peripheral administration of Norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic follow-up of complications from peripheral administration of Norepinephrine
Trial: NCT02199041
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by intravenous infusion as part of the preparative regimen.
Trial: NCT01161914
Drug: Cerezyme®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered by IV infusion for a dose of 60 U/kg
Trial: NCT01161914
Drug: ISU302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered by IV infusion for a dose of 60 U/kg
Trial: NCT03041935
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT03041935
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT00366145
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 infusions per week for 4 weeks
Trial: NCT00366145
Drug: Standard of Care for GVHD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Institutionally defined standard of care (e.g., maintenance of steroid treatment and the addition of a second-line therapy)
Trial: NCT03787251
Drug: The chemotherapeutic drug chosen by the investigator.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The choice of chemotherapy regimen is based on the medication habits of the drug delivery doctor and the specific circumstances of the patient.~In addition, the following regimens may be selected as monotherapy or combination: docetaxel 60-75 mg/m2d1 q3w; irinotecan 150-180 mg/m2 d1 q2w until disease progression or patient death. If grade 3 and above or non-hematologic toxicity of grade II and above adverse event appeared, allowing the dose to be lowered twice.
Trial: NCT01453634
Drug: Lunacalcipol 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
Trial: NCT01453634
Drug: Lunicalcipol 270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
Trial: NCT01287897
Drug: PF-04236921 SC injection
RxNorm normalized name: taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo delivered SC, 2 doses separated by 4 weeks
Trial: NCT01287897
Drug: PF-04236921 SC injection
RxNorm normalized name: taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug dose level 1 delivered SC, 2 doses separated by 4 weeks
Trial: NCT01287897
Drug: PF-04236921 SC injection
RxNorm normalized name: taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug dose level 2 delivered SC, 2 doses separated by 4 weeks
Trial: NCT00249444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01499667
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo in capsules for oral administration once daily.
Trial: NCT02673489
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01918904
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A small amount of topical zinc oxide and aquaphor cream twice daily (bid)
Trial: NCT01300780
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 - experimental Etoricoxib will receive two doses of selective anti-inflammatory to enzyme cyclooxygenase 2 (COX-2) (Etoricoxib 60 mg) given once every 24 hours;
Trial: NCT03041935
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT01758094
Drug: Sustanon 250 mg ampule (Testosterone esters)
RxNorm normalized name: testosterone enanthate 250 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug used for treatment of hypogonadism
Trial: NCT01897532
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching tablets
Trial: NCT01627886
Drug: Ibandronate sodium
RxNorm normalized name: Ibandronate Sodium
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate sodium Tablets 150 mg
Trial: NCT03646357
Drug: Betablocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A betablocker will be administered. To reflect contemporary management, for which this study is designed to test, there will not be a defined minimum dosage. The type and dose of BB will be left at the discretion of the PI. Generic drug and accepted dosages will be:~* Metoprolol succinate up to a total dose of 200mg daily~* Bisoprolol up to a total dose of 10mg daily~* Carvedilol up to a total dose of 50mg daily~The treating physician will be encouraged to aim for an equipotent dose of 100 mg metoprolol succinate or higher. Any other treatment or management is to be given as per usual care.
Trial: NCT03721822
Drug: [18F]NOS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]NOS is an investigational radiotracer which each subject will have one \[18F\]NOS positron emission tomography/computed tomography (PET/CT) scan performed.
Trial: NCT03538743
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 0 mg, twice daily, 28 days
Trial: NCT01978483
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04470388
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match EDP-514
Trial: NCT03728933
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: not applicable
Trial: NCT01317992
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 4 capsules, orally, twice daily for 8 weeks.
Trial: NCT00582907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo by subcutaneous injection weekly for 3 months
Trial: NCT02403544
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine: by oral, D1-14, every 21 days, 600mg/m2 bid per day in level 1, and then escalated every another dose level.
Trial: NCT00186628
Drug: Mycophenylate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenylate mofetil (MMF) will be administered at 15 mg/kg po Day 0, at 5 to 10 hours after mobilized PBPC infusion is complete
Trial: NCT00186628
Drug: Solumedrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solumedrol, an anti-inflammatory glucocorticoid containing methylprednisolone sodium succinate, administered at 1 mg/kg as a premedication for anti-thymoglobulin (ATG)
Trial: NCT00186628
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen administered orally at 650 mg 1 hour prior to infusion of PBPC
Trial: NCT00186628
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone administered by intravenous infusion at 100 mg 1 hour prior to infusion of PBPC
Trial: NCT00089622
Drug: Intravenous Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02125344
Drug: non-pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/m2, i.V. 18 times weekly
Trial: NCT02125344
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2000 mg/m² every 2 weeks for 3 cycles.
Trial: NCT02923154
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04344730
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Box of 10 NaCl 0,9% , solution for injection in ampoule of 5mL. Each allocated box contains complete treatment from D1 to D10 for one patient.
Trial: NCT03383042
Drug: Cohort 1 (JP-1366 A mg)
RxNorm normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [JP P Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: JP-1366 A mg or JP-1366 Placebo or Esomeprazole 40 mg
Trial: NCT03383042
Drug: Cohort 3 (JP-1366 C mg)
RxNorm normalized name: FD & C RED #3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: JP-1366 C mg or JP-1366 Placebo or Esomeprazole 40 mg
Trial: NCT03383042
Drug: Cohort 6 (JP-1366 F mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: JP-1366 F mg or JP-1366 Placebo or Esomeprazole 40 mg
Trial: NCT03383042
Drug: Cohort 7 (JP-1366 G mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: JP-1366 G mg or JP-1366 Placebo or Esomeprazole 40 mg
Trial: NCT03383042
Drug: Cohort 8 (JP-1366 H mg)
RxNorm normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [JP P Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: JP-1366 H mg or JP-1366 Placebo or Esomeprazole 40 mg
Trial: NCT01130337
Drug: Capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.000 mg/m2 orally every 12 hours from day 1 to day 14 of every cycle for 6 cycles
Trial: NCT03901638
Drug: Tllsh2910
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tllsh2910 80mg twice per day orally for 12 weeks
Trial: NCT03901638
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03553537
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750mg/m² iv on day 6
Trial: NCT03553537
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DOX
Trial: NCT03101319
Drug: B Complex Oral Tablet
RxNorm normalized name: vitamin B complex Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As mentioned in the description of the study arm
Trial: NCT02049411
Drug: physiological solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: physiological solution at 0.9% (250 ml) during 2 hours, intravenously, with the same physical characteristics of ketamine.
Trial: NCT00929214
Drug: Standard Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and/or Endocrine Therapy:~For 3 - 9 months, all patients will receive systemic chemotherapy agents appropriate for the tumor characteristics and patient's prior treatment history, and may also be placed on endocrine therapy as determined by the treating medical oncologist.
Trial: NCT00730054
Drug: Remifentanil+clonidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv Remifentanil+ iv clonidine
Trial: NCT03971929
Drug: SHR0532
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily(QD) for 4weeks
Trial: NCT03971929
Drug: SHR placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily(QD) for 4weeks
Trial: NCT00541112
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00541112
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00541112
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02412670
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02412670
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00565409
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week).
Trial: NCT00565409
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC), once weekly from week 36 to week 88.
Trial: NCT01425476
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
Trial: NCT01425476
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
Trial: NCT02832570
Drug: Placebo, Oral intake single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
Trial: NCT00654537
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00654537
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00654537
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02249403
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02325063
Drug: Corticoid injection
RxNorm normalized name: Corticool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with an injection of Corticoids.
Trial: NCT01726374
Drug: BEP(500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One cycle of BEP(500):~Etoposide 165 mg/m2 IV infusion - days 1, 2, 3 Cisplatin 50 mg/m2 IV infusion - days 1, 2 Bleomycin 30,000 IU IV infusion - days 1 (or 2), 8, 15
Trial: NCT04153487
Drug: Ascorbic Acid Injectable Product
RxNorm normalized name: ascorbic acid Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Intravenous Infusion of Ascorbic Acid (Vitamin C) 2.5 gm / 6 hours for 96 hours
Trial: NCT04153487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo saline / 6 hours for 96 hours
Trial: NCT00265850
Drug: FOLFOX or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive oxaliplatin 85 mg/m\^2 IV infused over two hours followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus, then 2400 mg/m\^2 continuous IV infusion over 46-48 hours
Trial: NCT00265850
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive irinotecan 180 mg/m\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus following leucovorin then 2400 mg/m\^2 continuous IV infusion over 46-48 hours.
Trial: NCT04031729
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical, blinded placebo tablets will be given once daily, for the duration of the clinical trial.
Trial: NCT03961126
Drug: Injection of autologous fatty tissue associated with autologous platelet-rich plasma.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 2 separate infiltrations for three months by intra and subdermal injection of autologous fatty tissue (20cc) associated with autologous platelet-rich plasma (4cc) in each half vulvar.
Trial: NCT03961126
Drug: Corticosteroids (clobetasol 0.05%)
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a maintenance treatment of topical therapy with corticosteroids (clobetasol 0.05%) that will be administered by usual clinical practice.
Trial: NCT00332696
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic saline solution
Trial: NCT00114491
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00382174
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of 0.00% thymosin beta 4 qd up to 84 days
Trial: NCT00961038
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), placebo will be given twice daily, with a concluding single dose (on day 12)